IBT6A
产品说明书
 |
同义名 : | 依鲁替尼中间体 |
| CAS号 : | 1022150-12-4 | |
| 货号 : | A110162 | |
| 分子式 : | C22H22N6O | |
| 纯度 : | 98% | |
| 分子量 : | 386.45 | |
| MDL号 : | MFCD20482137 | |
| 存储条件： |
Pure form Keep in dark place, inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Btk inhibitor 1 R enantiomer is a pyrazolo[3,4-d]pyrimidine derivative as a Btk kinase inhibitor. Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase member of the Tec kinase family, is involved in B cell receptor(BCR) signalling and governs B-lymphocyte development, differentiation, signalling and survival[2]. Ibrutinib is a covalent and irreversible inhibitor of Bruton's tyrosine kinase (BTK) and has been approved for the treatment of haematological malignancies. Ibrutinib irreversibly blocks BTK activity through covalent modification of Cys481. Btk inhibitor 1 R enantiomer can be used in synthesis of Ibrutinib and ibrutinib-based activity-based probes (ABPs)[2]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.59mL 0.52mL 0.26mL |
12.94mL 2.59mL 1.29mL |
25.88mL 5.18mL 2.59mL |
| 参考文献 |
|---|